Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2016 | Pages:
112 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H1 2016', provides an overview of the Vancomycin-Resistant Enterococcus faecium Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vancomycin-Resistant Enterococcus faecium Infections and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Enterococcus faecium Infections - The report reviews pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Vancomycin-Resistant Enterococcus faecium Infections therapeutics and enlists all their major and minor projects - The report assesses Vancomycin-Resistant Enterococcus faecium Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Vancomycin-Resistant Enterococcus faecium Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Vancomycin-Resistant Enterococcus faecium Infections Overview 10 Therapeutics Development 11 Pipeline Products for Vancomycin-Resistant Enterococcus faecium Infections - Overview 11 Pipeline Products for Vancomycin-Resistant Enterococcus faecium Infections - Comparative Analysis 12 Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics under Development by Companies 13 Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics under Investigation by Universities/Institutes 15 Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Products Glance 16 Clinical Stage Products 16 Early Stage Products 17 Vancomycin-Resistant Enterococcus faecium Infections - Products under Development by Companies 18 Vancomycin-Resistant Enterococcus faecium Infections - Products under Investigation by Universities/Institutes 20 Vancomycin-Resistant Enterococcus faecium Infections - Companies Involved in Therapeutics Development 21 Alchemia Limited 21 Alvogen Korea Co., Ltd. 22 Aphios Corporation 23 Cellceutix Corporation 24 Helix BioMedix, Inc. 25 Hsiri Therapeutics, LLC 26 LegoChem Biosciences, Inc 27 Lytix Biopharma AS 28 MGB Biopharma Limited 29 MicuRx Pharmaceuticals, Inc. 30 Nanotherapeutics, Inc. 31 NovaBay Pharmaceuticals, Inc. 32 NovoBiotic Pharmaceuticals, LLC 33 Oragenics, Inc. 34 Sealife PHARMA GMBH 35 Sentinella Pharmaceuticals, Inc. 36 TAXIS Pharmaceuticals, Inc. 37 Wockhardt Limited 38 Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics Assessment 39 Assessment by Monotherapy Products 39 Assessment by Target 40 Assessment by Mechanism of Action 42 Assessment by Route of Administration 44 Assessment by Molecule Type 46 Drug Profiles 48 AM-218 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 auriclosene - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 brilacidin tetrahydrochloride - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 chrysophaentin - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 closthioamide - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Epimerox - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 HB-1345 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 HT-01 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 HT-02 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 IBN-1 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 LCB-010371 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 LCB-010699 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 LTX-109 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Marinus - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 MGBBP-3 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 MRX-I - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 MRX-IV - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 NAI-107 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 NAI-603 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 OG-253 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 ramoplanin - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 SLP-0904 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 SLP-0905 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 Small Molecule to Inhibit Glycosyltransferase for Bacterial Infection - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Small Molecules for Bacterial Infections - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 Small Molecules to Inhibit FtsZ Protein for MRSA and VRE Infections - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 SP-2078 - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Teixobactin - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 WCK-4086 - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 Vancomycin-Resistant Enterococcus faecium Infections - Recent Pipeline Updates 88 Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects 105 Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products 106 Vancomycin-Resistant Enterococcus faecium Infections - Product Development Milestones 107 Featured News & Press Releases 107 Feb 25, 2015: MicuRx Initiates U.S. Phase 2 Clinical Trial For Novel Antibiotic MRX-I 107 Aug 26, 2013: Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project 107 Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140 108 Sep 12, 2012: NovaBay Pharma Announces Data From New Study Demonstrating Chemical Impact Of N-chlorotaurine And NVC-422 On Bacterial Toxins 108 May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent 109 Apr 23, 2012: MicuRx Completes Phase I Trial For MRX-I 109 Appendix 111 Methodology 111 Coverage 111 Secondary Research 111 Primary Research 111 Expert Panel Validation 111 Contact Us 111 Disclaimer 112
List of Tables
Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, H1 2016 11 Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 16 Comparative Analysis by Early Stage Development, H1 2016 17 Products under Development by Companies, H1 2016 18 Products under Development by Companies, H1 2016 (Contd..1) 19 Products under Investigation by Universities/Institutes, H1 2016 20 Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Alchemia Limited, H1 2016 21 Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Alvogen Korea Co., Ltd., H1 2016 22 Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Aphios Corporation, H1 2016 23 Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Cellceutix Corporation, H1 2016 24 Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Helix BioMedix, Inc., H1 2016 25 Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Hsiri Therapeutics, LLC, H1 2016 26 Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by LegoChem Biosciences, Inc, H1 2016 27 Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Lytix Biopharma AS, H1 2016 28 Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MGB Biopharma Limited, H1 2016 29 Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H1 2016 30 Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Nanotherapeutics, Inc., H1 2016 31 Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by NovaBay Pharmaceuticals, Inc., H1 2016 32 Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by NovoBiotic Pharmaceuticals, LLC, H1 2016 33 Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Oragenics, Inc., H1 2016 34 Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Sealife PHARMA GMBH, H1 2016 35 Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Sentinella Pharmaceuticals, Inc., H1 2016 36 Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by TAXIS Pharmaceuticals, Inc., H1 2016 37 Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Wockhardt Limited, H1 2016 38 Assessment by Monotherapy Products, H1 2016 39 Number of Products by Stage and Target, H1 2016 41 Number of Products by Stage and Mechanism of Action, H1 2016 43 Number of Products by Stage and Route of Administration, H1 2016 45 Number of Products by Stage and Molecule Type, H1 2016 47 Vancomycin-Resistant Enterococcus faecium Infections Therapeutics - Recent Pipeline Updates, H1 2016 88 Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects, H1 2016 105 Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products, H1 2016 106
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
